Medication Dispensary Hazardous Drugs Within the VTH
Reference: NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 (cdc.gov)
Group 1: Antineoplastic drugs: An agent with antineoplastic properties such as cancer chemotherapy drugs and/or cytotoxic drugs.
|
Asparaginase (Elspar) |
|
Azathioprine |
|
Carboplatin |
|
Chloramphenicol |
|
Cyclophosphamide |
|
Cyclosporine (Cyclavance/Atopica) (Optimmune Ophthalmic Ointment) |
|
Cytarabine (Cytosar) |
|
Dacarbazine |
|
Dexrazoxane |
|
Doxorubicin |
|
Epirubicin |
|
Gemcitabine |
|
Imatinib (Gleevec) |
|
Lomustine (CCNU) |
|
Lutalyse (Dinoprost Tromethamine) |
|
Mitomycin |
|
Mitoxantrone |
|
Mycophenolate mofetil |
|
Procarbazine |
|
Rabacfosadine (Tanovea) |
|
Temozolomide |
|
Toceranib (Palladia) |
|
Vinblastine |
|
Vincristine |
|
Vinorelbine |
Group 2: Non-antineoplastic drugs: Drugs that meet one or more of the NIOSH criteria for a hazardous drug. Some of these drugs may also pose a reproductive risk for susceptible populations.
|
Apomorphine |
|
DMSO (Dimethyl Sulfoxide) |
|
Estradiol |
|
Fluconazole |
|
Fosphenytoin |
|
Methimazole |
|
Misoprostol |
|
Oclacitinib (Apoquel) |
|
Olaparib |
|
Oxytocin |
|
Pergolide |
|
Spironolactone |
|
Tacrolimus (Ophthalmic Solution/Suspension) |
|
Trilostane (Vetoryl) |
|
Voriconazole |
|
Tylosin |
|
Zoledronic Acid (Zometa) |
|
Zonisamide |
Group 3: Reproductive-only hazards: Drugs that primarily pose a reproductive risk to men and women who are actively trying to conceive and women who are pregnant or breastfeeding.
|
Regu-Mate (Altrenogest) |
|
Synotic Otic Solution (fluocinolone acetonide) |